155 related articles for article (PubMed ID: 37763083)
1. Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells.
Drzewiecka M; Jaśniak D; Barszczewska-Pietraszek G; Czarny P; Kobrzycka A; Wieczorek M; Radek M; Szemraj J; Skorski T; Śliwiński T
J Pers Med; 2023 Aug; 13(9):. PubMed ID: 37763083
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor.
Drzewiecka M; Gajos-Michniewicz A; Hoser G; Jaśniak D; Barszczewska-Pietraszek G; Sitarek P; Czarny P; Piekarski J; Radek M; Czyż M; Skorski T; Śliwiński T
Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372475
[TBL] [Abstract][Full Text] [Related]
3. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
Krumm A; Barckhausen C; Kücük P; Tomaszowski KH; Loquai C; Fahrer J; Krämer OH; Kaina B; Roos WP
Cancer Res; 2016 May; 76(10):3067-77. PubMed ID: 26980768
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
7. VPA and TSA Interrupt the Interplay between mutp53 and HSP70, Leading to CHK1 and RAD51 Down-Regulation and Sensitizing Pancreatic Cancer Cells to AZD2461 PARP Inhibitor.
Romeo MA; Gilardini Montani MS; Benedetti R; Arena A; D'Orazi G; Cirone M
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216385
[TBL] [Abstract][Full Text] [Related]
8. Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent.
Toma M; Witusik-Perkowska M; Szwed M; Stawski R; Szemraj J; Drzewiecka M; Nieborowska-Skorska M; Radek M; Kolasa P; Matlawska-Wasowska K; Sliwinski T; Skorski T
Oncotarget; 2018 Dec; 9(96):36867-36877. PubMed ID: 30627327
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.
Robert C; Nagaria PK; Pawar N; Adewuyi A; Gojo I; Meyers DJ; Cole PA; Rassool FV
Leuk Res; 2016 Jun; 45():14-23. PubMed ID: 27064363
[TBL] [Abstract][Full Text] [Related]
10. Effect of valproic acid on the outcome of glioblastoma multiforme.
Tsai HC; Wei KC; Tsai CN; Huang YC; Chen PY; Chen SM; Lu YJ; Lee ST
Br J Neurosurg; 2012 Jun; 26(3):347-54. PubMed ID: 22168970
[TBL] [Abstract][Full Text] [Related]
11. The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines.
Chang YL; Huang LC; Chen YC; Wang YW; Hueng DY; Huang SM
Int J Biochem Cell Biol; 2017 Nov; 92():155-163. PubMed ID: 29017950
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
13. Cross-reactivity between histone demethylase inhibitor valproic acid and DNA methylation in glioblastoma cell lines.
Barciszewska AM; Belter A; Gawrońska I; Giel-Pietraszuk M; Naskręt-Barciszewska MZ
Front Oncol; 2022; 12():1033035. PubMed ID: 36465345
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Redjal N; Reinshagen C; Le A; Walcott BP; McDonnell E; Dietrich J; Nahed BV
J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
16. Opposing Effects of Valproic Acid Treatment Mediated by Histone Deacetylase Inhibitor Activity in Four Transgenic
Vent-Schmidt RYJ; Wen RH; Zong Z; Chiu CN; Tam BM; May CG; Moritz OL
J Neurosci; 2017 Jan; 37(4):1039-1054. PubMed ID: 28490005
[TBL] [Abstract][Full Text] [Related]
17. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET
Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors.
Dedoni S; Marras L; Olianas MC; Ingianni A; Onali P
J Pharmacol Exp Ther; 2019 Sep; 370(3):490-503. PubMed ID: 31308194
[TBL] [Abstract][Full Text] [Related]
19. Molecular dissection of the valproic acid effects on glioma cells.
Hoja S; Schulze M; Rehli M; Proescholdt M; Herold-Mende C; Hau P; Riemenschneider MJ
Oncotarget; 2016 Sep; 7(39):62989-63002. PubMed ID: 27556305
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide resistance in glioblastoma multiforme.
Lee SY
Genes Dis; 2016 Sep; 3(3):198-210. PubMed ID: 30258889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
